Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Japanese encephalitis inactivated vaccine is a biologic vaccine used to prevent infection caused by the Japanese encephalitis virus (JEV), a mosquito-borne flavivirus that can cause severe neurological disease. The inactivated vaccines are produced using Vero cell culture technology and work by stimulating the immune system to produce protective antibodies against JEV. The primary indication is for individuals traveling to or living in areas where Japanese encephalitis is endemic, as well as for military personnel and laboratory workers at risk of exposure. The most widely used brands include IXIARO (manufactured by Valneva) and JEspect. These vaccines are administered intramuscularly, typically as a two-dose series spaced 28 days apart. Inactivated vaccines are preferred for immunocompromised individuals and pregnant women due to their safety profile[1][2][3][4][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Japanese encephalitis inactivated vaccine.